BLCM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BLCM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bellicum Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2023 was -62.83%.
The historical data trend for Bellicum Pharmaceuticals's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellicum Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
ROCE % | Get a 7-Day Free Trial | -81.93 | -169.68 | -26.85 | -83.64 | -86.36 |
Bellicum Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
ROCE % | Get a 7-Day Free Trial | -99.50 | -128.81 | -212.18 | -317.71 | -62.83 |
Bellicum Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2022 ) | (A: Dec. 2021 ) | (A: Dec. 2022 ) | |||||
= | -26.981 | / | ( ( (49.143 - 6.712) | + | (23.823 - 3.772) ) | / 2 ) | |
= | -26.981 | / | ( (42.431 | + | 20.051) | / 2 ) | |
= | -26.981 | / | 31.241 | ||||
= | -86.36 % |
Bellicum Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Sep. 2023 ) | (Q: Jun. 2023 ) | (Q: Sep. 2023 ) | |||||
= | -3.096 | / | ( ( (8.733 - 3.482) | + | (6.853 - 2.249) ) | / 2 ) | |
= | -3.096 | / | ( ( 5.251 | + | 4.604 ) | / 2 ) | |
= | -3.096 | / | 4.9275 | ||||
= | -62.83 % |
(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellicum Pharmaceuticals (OTCPK:BLCM) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Charity Scripture | officer: Chief Development Officer | C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098 |
James M Daly | director | INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880 |
Stephen Davis | director | ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Charles S. Grass | officer: Principal Accounting Officer | C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Richard A. Fair | director, officer: President and CEO | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
David Eric Strauss | officer: Director, Corporate Controller | 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Shane Ward | officer: Sr. VP and General Counsel | C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
Woodard Jr Joseph Paul | officer: SVP Clinical & Medical Affairs | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Aaron E. Foster | officer: Sr VP, Head of Research | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030 |
Rosemary Y. Williams | officer: Principal Accounting Officer | 2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030 |
Judith V Klimovsky | director | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Atabak Mokari | officer: Sr. VP and CFO | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Jon P Stonehouse | director | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
David M. Spencer | officer: Chief Scientific Officer | C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
Alan A Musso | officer: CFO and Treasurer | FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
From GuruFocus
By Marketwired Marketwired • 09-03-2021
By GF Value GF Value • 04-17-2021
By Marketwired Marketwired • 09-01-2021
By Value_Insider Value_Insider • 12-11-2022
By GuruFocusNews GuruFocusNews • 01-26-2022
By Stock market mentor Stock market mentor • 01-19-2023
By Marketwired Marketwired • 08-12-2021
By Marketwired Marketwired • 07-26-2021
By GlobeNewswire GlobeNewswire • 12-11-2022
By Ds*** Ds*** • 09-01-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.